Drug Profile
Naxitamab - Y mAbs Therapeutics
Alternative Names: DANYELZA; Danyelza; Hu3F8; Hu3F8 (GD2); Hu3F8-Fce; Humanised 3F8; Humanised anti-GD2 3F8 monoclonal antibody - Memorial Sloan-Kettering Cancer Center/Y-mAbs Therapeutics; Humanised IgG1 monoclonal GD2 antibody - Memorial Sloan-Kettering Cancer Center/Y-mAbs Therapeutics; Naxitamab-gqgkLatest Information Update: 23 Apr 2024
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Memorial Sloan-Kettering Cancer Center; SciClone Pharmaceuticals; Takeda Israel; Wake Forest University Health Sciences; Y-mAbs Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Neuroblastoma
- Phase II Osteosarcoma
- Discontinued Sarcoma; Small cell lung cancer; Triple negative breast cancer
Most Recent Events
- 23 Apr 2024 Y-mAbs Therapeutics plans an investigator-initiated phase Ib/II trial for Breast cancer (Metastatic disease) in the first half of 2024
- 31 Dec 2023 Y mAbs Therapeutics has a patent pending for composition of matter claims covering high affinity anti‑GD2 antibodies in Taiwan
- 31 Dec 2023 Launched for Neuroblastoma (Combination therapy, In adolescents, In children, In the elderly, In infants, Second-line therapy or greater, In adults) in Israel (IV), prior to December 2023